What is 35Pharma?
35Pharma is a clinical-stage biopharmaceutical company focused on pioneering novel therapeutics within the TGF-beta superfamily, with a particular emphasis on Activin and GDF biology. The company's lead candidate, HS235, is currently undergoing clinical development for critical conditions such as pulmonary hypertension, heart failure, and obesity, areas marked by substantial unmet medical needs. By employing sophisticated protein engineering techniques, 35Pharma designs highly selective and potent multi-specific ligand traps, a strategy that facilitates accelerated clinical trial pathways. The company's experienced team is adept at advancing complex biologics, positioning 35Pharma to potentially deliver transformative treatments that enhance patient outcomes.
How much funding has 35Pharma raised?
35Pharma has raised a total of $53M across 1 funding round:
Series C
$53M
Series C (2024): $53M with participation from Vivo Capital, Frazier Life Sciences Management, and Deep Track Capital
Key Investors in 35Pharma
Vivo Capital
Vivo Capital, established in 1996, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital, indicating a broad investment mandate within the life sciences sector.
Frazier Life Sciences Management
Frazier Life Sciences is a prominent biotech investment firm known for its venture and public strategies, supporting companies from early development to commercialization. Their extensive track record includes significant capital managed and numerous successful exits, highlighting their expertise in advancing novel therapeutics.
Deep Track Capital
Deep Track Capital is an investment firm based in Greenwich, Connecticut, exclusively focused on the biotechnology sector. Their specialized approach suggests a deep understanding of the unique challenges and opportunities within the life sciences industry.
What's next for 35Pharma?
The substantial enterprise-level funding indicates a pivotal growth phase for 35Pharma, likely enabling the acceleration of its clinical development pipeline and the expansion of its research and development capabilities. This strategic investment will be crucial for advancing HS235 through further clinical trials and potentially preparing for commercialization. The company's focus on a well-defined biological pathway and experienced leadership suggests a clear trajectory toward addressing significant therapeutic challenges in cardiovascular and metabolic diseases.
See full 35Pharma company page
